- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07556159
En studie som utvärderar sjukdomsegenskaper och utfall hos deltagare med astma i rutinmässig klinisk praxis (AIRITY)
En hybrid tvärsnitts- och prospektiv studie för att bedöma patientkarakteristika, sjukdomsbörda, sjukdomskontroll, fenotyper, endotyper och utfall i en verklig miljö hos patienter med astma
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life.
The study consists of two parts: a cross-sectional study, and a prospective follow-up evaluate changes in disease trajectories in participants with asthma.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Trial Transparency email recommended-Toll free for US & Canada
- Telefonnummer: 6 800-633-1610
- E-post: Contact-US@sanofi.com
Studieorter
-
-
Brittany Region
-
Brest, Brittany Region, Frankrike, 29200
- Rekrytering
- Investigational Site Number: 250603
-
-
Occitanie
-
Lunel, Occitanie, Frankrike, 34400
- Rekrytering
- Investigational Site Number: 250612
-
Toulouse, Occitanie, Frankrike, 31059
- Rekrytering
- Investigational Site Number: 250607
-
-
Pays de la Loire Region
-
La Roche-sur-Yon, Pays de la Loire Region, Frankrike, 85000
- Rekrytering
- Investigational Site Number: 250613
-
-
Île-de-France Region
-
Argenteuil, Île-de-France Region, Frankrike, 95100
- Rekrytering
- Investigational Site Number: 250616
-
Créteil, Île-de-France Region, Frankrike, 94010
- Rekrytering
- Investigational Site Number: 250609
-
-
-
-
Alabama
-
Bessemer, Alabama, Förenta staterna, 35022
- Rekrytering
- Trinity Clinical Research, LLC - Bessemer - Site Number: 840150
-
-
Arizona
-
Chandler, Arizona, Förenta staterna, 85224
- Indragen
- Chandler Clinical Trials - Site Number: 840106
-
Mesa, Arizona, Förenta staterna, 85206
- Aktiv, inte rekryterande
- Del Sol Research Management, LLC - Mesa - Site Number: 840123
-
Scottsdale, Arizona, Förenta staterna, 85254
- Rekrytering
- Orso Health - Scottsdale - Site Number: 840133
-
Sun City, Arizona, Förenta staterna, 85351
- Aktiv, inte rekryterande
- Sun City Clinical Trials - Elite - Site Number: 840120
-
-
California
-
California City, California, Förenta staterna, 91107
- Aktiv, inte rekryterande
- FOMAT - Huntington Asthma & Allergy Center - Site Number: 840158
-
La Palma, California, Förenta staterna, 90623
- Aktiv, inte rekryterande
- Imax Clinical Trials - Site Number: 840109
-
Los Angeles, California, Förenta staterna, 90017
- Aktiv, inte rekryterande
- Downtown LA Research - Site Number: 840161
-
Newport Beach, California, Förenta staterna, 92663
- Aktiv, inte rekryterande
- Newport Native MD, Inc. - Site Number: 840101
-
Pasadena, California, Förenta staterna, 91101
- Aktiv, inte rekryterande
- Pasadena Clinical Trials - Site Number: 840116
-
Tarzana, California, Förenta staterna, 91356
- Indragen
- Valiance Clinical Research (JPJ Research) - Site Number: 840135
-
Walnut Creek, California, Förenta staterna, 94598
- Aktiv, inte rekryterande
- Clinical Research of California - Site Number: 840145
-
-
Florida
-
Altamonte Springs, Florida, Förenta staterna, 32701
- Aktiv, inte rekryterande
- Cornerstone Research Institute, LLC - Site Number: 840152
-
Boca Raton, Florida, Förenta staterna, 33431
- Aktiv, inte rekryterande
- 3SYNC Research - Boca Raton - Site Number: 840148
-
Brandon, Florida, Förenta staterna, 33511
- Aktiv, inte rekryterande
- Meris Clinical Research - Site Number: 840167
-
Greenacres City, Florida, Förenta staterna, 33467
- Aktiv, inte rekryterande
- Finlay Medical Research - Site Number: 840107
-
Miami, Florida, Förenta staterna, 33126
- Aktiv, inte rekryterande
- EMDA Clinical Research - Site Number: 840113
-
Miami, Florida, Förenta staterna, 33126
- Aktiv, inte rekryterande
- Finlay Medical Research - Miami - Site Number: 840110
-
Miami, Florida, Förenta staterna, 33130
- Aktiv, inte rekryterande
- Care Research Inc. - Site Number: 840103
-
Miami, Florida, Förenta staterna, 33142
- Aktiv, inte rekryterande
- L&A Morales Healthcare, Inc - Site Number: 840102
-
Miami, Florida, Förenta staterna, 33145
- Aktiv, inte rekryterande
- MedOne Clinical Research - Site Number: 840122
-
Miami, Florida, Förenta staterna, 33155
- Aktiv, inte rekryterande
- D&H National Research Centers INC - Site Number: 840128
-
Miami, Florida, Förenta staterna, 33173
- Aktiv, inte rekryterande
- Research Institute Of South Florida - Site Number: 840149
-
Miami, Florida, Förenta staterna, 33174
- Aktiv, inte rekryterande
- Valencia Medical & Research Center, Corp - Site Number: 840153
-
Miami, Florida, Förenta staterna, 33186
- Aktiv, inte rekryterande
- Correa Research Center, Inc. - Site Number: 840141
-
Miami Gardens, Florida, Förenta staterna, 33014
- Aktiv, inte rekryterande
- Pro Care Research Center - Site Number: 840143
-
Miami Lakes, Florida, Förenta staterna, 33014
- Aktiv, inte rekryterande
- 3SYNC Research - Miami Lakes - Site Number: 840146
-
Miami Lakes, Florida, Förenta staterna, 33014
- Aktiv, inte rekryterande
- Deluxe Health Center - Site Number: 840117
-
Miami Lakes, Florida, Förenta staterna, 33016
- Aktiv, inte rekryterande
- MedQuest Translation Sciences, LLC - Site Number: 840162
-
North Miami Beach, Florida, Förenta staterna, 33169
- Aktiv, inte rekryterande
- Biscayne Clinical Research - Site Number: 840157
-
Palm Springs, Florida, Förenta staterna, 33406
- Aktiv, inte rekryterande
- CTMD Research, Inc - Site Number: 840147
-
Plantation, Florida, Förenta staterna, 33317
- Aktiv, inte rekryterande
- Edward Jenner Research Group, LLC - Site Number: 840169
-
Port Saint Lucie, Florida, Förenta staterna, 34986
- Aktiv, inte rekryterande
- Mark J. Pamer D.O., LLC - Site Number: 840121
-
Tamarac, Florida, Förenta staterna, 33321
- Aktiv, inte rekryterande
- TBC Research Corp - Site Number: 840132
-
Tampa, Florida, Förenta staterna, 33613
- Aktiv, inte rekryterande
- Avita Clinical Research - Tampa - Site Number: 840125
-
West Palm Beach, Florida, Förenta staterna, 33409
- Aktiv, inte rekryterande
- Palm Beach Medical & Research Center, Inc. - Site Number: 840165
-
-
Georgia
-
Columbus, Georgia, Förenta staterna, 31904
- Aktiv, inte rekryterande
- The Allergy Center at Brookstone - Site Number: 840114
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60616
- Aktiv, inte rekryterande
- Next Innovation Clinical Research - Chicago - Site Number: 840159
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40509
- Aktiv, inte rekryterande
- Bluegrass Allergy Care - Lexington - Site Number:840112
-
-
Maryland
-
Columbia, Maryland, Förenta staterna, 21045
- Rekrytering
- Columbia Medical Practice - Site Number: 840172
-
Rockville, Maryland, Förenta staterna, 20854
- Aktiv, inte rekryterande
- Velocity Clinical Research - Rockville - Site Number: 840163
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- Rekrytering
- University of Michigan - Ann Arbor - Site Number: 840140
-
-
Montana
-
Missoula, Montana, Förenta staterna, 59808
- Aktiv, inte rekryterande
- Montana Medical Research - Site Number: 840137
-
-
Nebraska
-
Papillion, Nebraska, Förenta staterna, 68046
- Aktiv, inte rekryterande
- Primary Clinical Research, LLC - Papillion - Site Number: 840168
-
-
New Jersey
-
Sewell, New Jersey, Förenta staterna, 08080
- Aktiv, inte rekryterande
- MedCorps Asthma and Pulmonary Specialists LLC - Sewell - Site Number: 840136
-
-
New York
-
Cortland, New York, Förenta staterna, 13045
- Aktiv, inte rekryterande
- Finger Lakes Medical Research, PLLC - Site Number: 840155
-
New Windsor, New York, Förenta staterna, 12553
- Aktiv, inte rekryterande
- Mid Hudson Medical Research, PLLC - Site Number: 840139
-
New York, New York, Förenta staterna, 10029
- Aktiv, inte rekryterande
- Icahn School of Medicine at Mount Sinai - Center for Advanced Medicine - Site Number: 840119
-
-
North Carolina
-
Asheville, North Carolina, Förenta staterna, 28801
- Aktiv, inte rekryterande
- Allergy Partners of Western North Carolina - Site Number: 840131
-
Gastonia, North Carolina, Förenta staterna, 28054-7489
- Aktiv, inte rekryterande
- Clinical Research of Gastonia (CRG) - Site Number: 840160
-
Greenville, North Carolina, Förenta staterna, 27834-2849
- Rekrytering
- East Carolina University Physicians - Pulmonary and Critical Care Medicine - Site Number: 840142
-
-
Ohio
-
Lima, Ohio, Förenta staterna, 45801
- Aktiv, inte rekryterande
- NexGen Research - Site Number: 840154
-
Toledo, Ohio, Förenta staterna, 43617
- Aktiv, inte rekryterande
- Toledo Institute of Clinical Research Inc - Site Number: 840105
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15241
- Aktiv, inte rekryterande
- Allergy and Clinical Immunology Associates - Site Number: 840127
-
-
South Carolina
-
Rock Hill, South Carolina, Förenta staterna, 29732
- Aktiv, inte rekryterande
- Clinical Research of Rock Hill - Site Number: 840115
-
-
Tennessee
-
Tennessee City, Tennessee, Förenta staterna, 30909
- Aktiv, inte rekryterande
- Allergy Associates, PA dba Allergy, Asthma and Sinus Center - Site Number: 840144
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75235
- Aktiv, inte rekryterande
- Southwest Family Medicine Associates - Site Number: 840126
-
El Paso, Texas, Förenta staterna, 79902
- Aktiv, inte rekryterande
- El Paso Pulmonary Association (EPPA) - West El Paso - Site Number: 840108
-
Houston, Texas, Förenta staterna, 77090
- Aktiv, inte rekryterande
- Lumi Research - Site Number: 840156
-
Houston, Texas, Förenta staterna, 77099
- Aktiv, inte rekryterande
- Pioneer Research Solutions - Site Number: 840104
-
Hurst, Texas, Förenta staterna, 76054
- Aktiv, inte rekryterande
- Lumi Research - Hurst - Site Number: 840164
-
Tomball, Texas, Förenta staterna, 77081
- Aktiv, inte rekryterande
- DM Clinical - Tomball - Site Number: 840130
-
-
Washington
-
Bellingham, Washington, Förenta staterna, 98225
- Aktiv, inte rekryterande
- Bellingham Asthma, Allergy & Immunology Clinic - Site Number: 840138
-
-
-
-
-
Niigata, Japan
- Rekrytering
- Investigational Site Number: 392707
-
-
Fukuoka
-
Kitakyushu-Shi, Fukuoka, Japan, 802-0083
- Rekrytering
- Investigational Site Number: 392705
-
-
Kagawa-ken
-
Takamatsu, Kagawa-ken, Japan, 761-8073
- Rekrytering
- Investigational Site Number: 392702
-
-
Saga-ken
-
Saga, Saga-ken, Japan, 849-8501
- Rekrytering
- Investigational Site Number: 392711
-
-
Tokyo
-
Bunkyo-ku, Tokyo, Japan, 113-8431
- Rekrytering
- Investigational Site Number: 392710
-
tabashi City, Tokyo, Japan, 173-8610
- Rekrytering
- Investigational Site Number: 392709
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T3R 1W7
- Rekrytering
- Investigational Site Number: 124203
-
-
Ontario
-
Windsor, Ontario, Kanada, N8X 2G1
- Rekrytering
- Investigational Site Number: 124201
-
-
Quebec
-
Trois-Rivières, Quebec, Kanada, G8T7A1
- Rekrytering
- Investigational Site Number: 124204
-
-
-
-
-
Madrid, Spanien, 28034
- Rekrytering
- Investigational Site Number: 724408
-
-
-
-
Bayern (Bavaria)
-
München, Bayern (Bavaria), Tyskland, 85039
- Rekrytering
- Investigational Site Number: 276503
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Tyskland, 53119
- Rekrytering
- Investigational Site Number: 276505
-
-
Saxony
-
Hohenstein-Ernstthal, Saxony, Tyskland, 09337
- Rekrytering
- Investigational Site Number: 276501
-
-
Schleswig-Holstein
-
Schleswig, Schleswig-Holstein, Tyskland, 24837
- Rekrytering
- Investigational Site Number: 276502
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Enrollment into Part 1 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible. In addition, enrollment is intended to include pediatric participants, adolescents, and adults. Enrollment into Part 2 is planned to achieve a balanced distribution of participants across participating regions, to the extent feasible.
Beskrivning
Inclusion Criteria:
Applicable for Part 1 participants:
- Age 6 years and older, at the time of signing the informed consent
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- Participant or legally authorized representative (where applicable) has consented to participate
Applicable for Part 2 participants:
- Age 18 years and older, at the time of signing the informed consent.
- Physician diagnosis of asthma for at least 12 months
- Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- Participant or legally authorized representative (where applicable) has consented to participate
- Participants must meet the criteria for at least one of the cohorts below:
A) Asthma control cohorts
- ACQ-5 >= 1.5
- ACQ-5 < 1.5 (B) Type-2 biomarker cohorts
- Elevated T2 biomarkers (B1: Type-2-high cohort)
- Low T2 biomarkers (B2: Type-2-low cohort)
Participants are excluded from the study if any of the following criteria apply (applicable for both Part 1 and Part 2 participants):
- Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- Participants with moderate/severe cognitive impairment.
- Participants with moderate/severe cardiac disease.
- Participants on immunosuppressive medication for a chronic condition.
- Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Part-1: Participants With Asthma
Participants receiving treatment with low-, medium-, or high-dose inhaled corticosteroids (ICS) and/or biologic therapies as part of standard of care (SoC) for the management of asthma in routine clinical practice. |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A1- Uncontrolled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of greater than or equal to (>=)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: A2- Controlled Asthma Cohort
Participants receiving SoC with Asthma Control Questionnaire-5 (ACQ-5) threshold of less than (<)1.5 |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B1- Type-2 (T2) High Asthma Cohort
Participants receiving SoC with elevated T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
|
Part-2: B2- Type-2 Low Asthma Cohort
Participants receiving SoC with low T2 biomarkers |
Participant- and physician-reported outcomes will be collected per protocol. No Investigational Medicinal Product (IMP) administration. Participant- and physician-reported outcomes, blood samples/lung tests and other optional assessments will be collected per protocol. No IMP administration. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Part 1: Descriptive Characterization of Participants With Asthma Across the Spectrum of Severities
Tidsram: Part 1: At baseline
|
Descriptive Statistical Analyses may include sociodemographic and clinical characteristics, comorbidities, exacerbation history, medication burden, biomarkers and lung function. |
Part 1: At baseline
|
|
Part 1: ACQ-5 Scores to Evaluate Characteristics of Participants With Asthma
Tidsram: Part 1: At baseline
|
ACQ-5 is a 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score ≤ 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the minimal clinically important difference (MCID) |
Part 1: At baseline
|
|
Part 1: Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Scores to Evaluate Characteristics of Participants With Asthma
Tidsram: Part 1: At baseline
|
The Asthma Quality of Life Questionnaire (AQLQ) includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. Higher scores indicating better quality of life (less impairment) and lower scores indicating worse quality of life (greater impairment). |
Part 1: At baseline
|
|
Part 1: Physician Global Assessment of Asthma Severity and Symptom Control
Tidsram: Part 1: At baseline
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: Physician Global Impression of Severity (PhGIS) - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 1: At baseline
|
|
Part 2: Descriptive Statistical Analysis of Difference in Asthma Symptom Control (ACQ-5) Between Part 2 Cohorts A1 and A2
Tidsram: Part 2: At Weeks 52 and 104
|
Data on participant's asthma symptoms and control will be collected via the ACQ-5, 5-question survey. The five ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), and the overall score is the mean of the five responses. Participant's scores are then classified into three prescribed groups as having well-controlled asthma (score <=0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). A change in ACQ-5 score of 0.5 is considered the MCID. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants Analyzed with Treatment Utilization Pattern between Part 2 Cohorts A1 and A2
Tidsram: Part 2: At Weeks 52 and 104
|
Treatment utilization will include systemic corticosteroids (SCS), ICS, and short-acting beta agonists (SABA). Number of participants with various treatment utilization pattern will be assessed and reported. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Descriptive Statistical Analysis of Difference in Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV₁) between Part 2 Cohorts B1 and Cohort B2
Tidsram: Part-2: At Weeks 52 and 104
|
Pre-BD FEV₁ is the forced expiratory volume in 1 second measured by spirometry prior to bronchodilator administration. |
Part-2: At Weeks 52 and 104
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Del 1: Antal deltagare karakteriserade efter demografi och kliniska egenskaper
Tidsram: Del 1: Från 12 månader före studiestart
|
Del 1: Från 12 månader före studiestart
|
|
|
Del 1: Antal deltagare karakteriserade utifrån sjukdomsbörda, hälsostatus och behandlingserfarenheter
Tidsram: Del 1: Från 12 månader före studiestart
|
Del 1: Från 12 månader före studiestart
|
|
|
Del 1: Antal deltagare karakteriserade efter läkemedelsanvändning
Tidsram: Del 1: Från 12 månader före studiestart
|
Del 1: Från 12 månader före studiestart
|
|
|
Del 1: Antal deltagare karakteriserade efter sina livsstils- och miljöpåverkan
Tidsram: Del 1: Från 12 månader före studiestart
|
Del 1: Från 12 månader före studiestart
|
|
|
Del 1: Antal deltagare karakteriserade genom användning av inhalerade och systemiska kortikosteroider
Tidsram: Del 1: Från 12 månader före studiestart
|
Del 1: Från 12 månader före studiestart
|
|
|
Del 1: Antal deltagare karakteriserade efter sjukvårdsresursutnyttjande (HCRU)
Tidsram: Del 1: Från 12 månader före studiestart
|
Del 1: Från 12 månader före studiestart
|
|
|
Del 2: Beskrivande karakterisering inklusive sociodemografi och sjukdomsegenskaper samt behandlingshistorik.
Tidsram: Del 2: Vid baslinjen
|
Del 2: Vid baslinjen
|
|
|
Del 2: Årlig exacerbationsfrekvens vecka 52 och 104
Tidsram: Del 2: Vid vecka 52 och 104
|
Del 2: Vid vecka 52 och 104
|
|
|
Del 2: Antal deltagare som analyserats för förändringar i inhalerad och systemisk kortikosteroidbörda
Tidsram: Del 2: Från baslinje upp till vecka 104
|
Del 2: Från baslinje upp till vecka 104
|
|
|
Del 2: Förändringar i biomarkörnivå
Tidsram: Del 2: Vid vecka 52 och 104
|
Del 2: Vid vecka 52 och 104
|
|
|
Part 1: Physician-Reported Outcomes to Characterize Physician Perspectives
Tidsram: Part 1: From 12 months prior to study enrollment
|
The treatment preferences for participant profiles, an assessment of perceived disease burden on participants, an evaluation of barriers to optimal treatment, and treatment adherence and persistence will be collected from the main treating physician. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Patient Global Impression of Severity (PGIS) Score
Tidsram: Part 1: From 12 months prior to study enrollment
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 1: Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score
Tidsram: Part 1: From 12 months prior to study enrollment
|
The WPAI-Asthma is an Asthma-specific, patient-reported measure of work absenteeism, work presenteeism (reduced productivity while working due to illness), total work productivity loss (absenteeism plus presenteeism), and overall activity impairment over the prior 7 days. The WPAI-Asthma questionnaire score represents the percentage of impairment, from 0 to 100%. Higher scores represent greater impairment and less productivity. |
Part 1: From 12 months prior to study enrollment
|
|
Part 2: Changes From Baseline to Week 104 in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsram: Part 2: From baseline to week 52 and week 104
|
FEV1 will be measured in Liters. Change from baseline: mean of (value of observed FEV1 at treatment duration minus baseline value). |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Significant Changes in Asthma Treatment Patterns at Week 52 and Week 104
Tidsram: Part 2: From baseline to week 52 and week 104
|
Changes in treatment patterns including use of SCS, ICS, other asthma therapies, and rescue medication. Treatment escalation (for example [e.g.], ICS dose changes, addition of asthma therapies, or biologic prescription), treatment adherence, and treatment persistence will be assessed from baseline to Week 52 and Week 104 in participants with Asthma. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Physician Global Assessment of Asthma Severity, Symptom Control and Comorbidities (PhGIS)
Tidsram: Part 2: From baseline to week 52 and week 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Participant Survey Using the PGIS scale
Tidsram: Part 2: At Weeks 52 and 104
|
The PGIS is a single question asking the participant to rate their severity and symptom control. The PGIS is a 5-point ordinal scale ranging from 1 (No symptoms) to 5 (Very severe symptoms). Higher scores indicate greater symptom severity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Number of Participants With Comorbidities and Burden of Comorbidities Based on the Physician Survey Using the PhGIS Scale
Tidsram: Part 2: At Weeks 52 and 104
|
Asthma severity, asthma control, and comorbidity will be assessed using three global impression of severity items: PhGIS - asthma severity. PhGIS - asthma control, and PhGIS - comorbidity. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Physician-reported HCRU (Hospitalizations, Outpatient and Emergency Visits)
Tidsram: Part 2: From baseline to week 52 and week 104
|
Data about HCRU associated with medical encounters will be collected by physicians from medical records. The data collected will include setting, department, type of specialist, the reasons and duration of hospitalizations, outpatient and emergency room (ER) visits. |
Part 2: From baseline to week 52 and week 104
|
|
Part 2: Changes in Patient-Reported Outcomes to Characterize Disease Evolution
Tidsram: Part 2: At Weeks 52 and 104
|
PROs used will include but not limited to ACQ-5, mini-AQLQ. ACQ-5 questions are scored on a 6-point scale (0 = good control, 6 = poor control), Mean of the five responses is the overall score. Scores are then classified into three groups as having well-controlled asthma (score <= 0.75); partially controlled asthma (score 0.75-1.5), or not well controlled asthma (score >1.5). AQLQ includes 32 items, The mini-AQLQ is a reduced version of the AQLQ which includes 15 items. The questions correspond to 4 dimensions of health: symptoms (5 items), limitation of usual activities (4 items), emotional function (3 items) and environmental stimuli (3 items). The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability. |
Part 2: At Weeks 52 and 104
|
|
Part 2: Changes in Participant Survey Response
Tidsram: Part 2: From baseline to week 52 and week 104
|
Participant survey collecting demographics, clinical characteristics, disease burden, health status, treatment experiences, medication use and burden, work and school impacts, lifestyle and environmental influences, impacts on daily life, PGIS for each comorbidity and burden of comorbidities, inhaled and systemic corticosteroid burden (frequency of use, routes of administration, treatment satisfaction), and HCRU office visits, hospitalizations, outpatient and emergency visits will be collected from medical records. |
Part 2: From baseline to week 52 and week 104
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PIR21191
- 2025-524916-13-00 (Ctis)
- U1111-1336-5183 (Registeridentifierare: ICTRP)
- 2025 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .